Targets › TB4
1 program from 1 company in 1 trial: 1 Phase 3; Ophthalmology.
Open in Phaseline: the race on TB4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ReGenTree | RGN-259 Thymosin beta 4 (Tβ4) analogue | TB4 | Phase 3 | Neurotrophic Keratopathy | – |
Neurotrophic Keratopathy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.